CN101472586A - 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法 - Google Patents

用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法 Download PDF

Info

Publication number
CN101472586A
CN101472586A CNA2007800232331A CN200780023233A CN101472586A CN 101472586 A CN101472586 A CN 101472586A CN A2007800232331 A CNA2007800232331 A CN A2007800232331A CN 200780023233 A CN200780023233 A CN 200780023233A CN 101472586 A CN101472586 A CN 101472586A
Authority
CN
China
Prior art keywords
agonist
functional
muscarine
treatment
officinal salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800232331A
Other languages
English (en)
Chinese (zh)
Inventor
P·C·夏普
P·R·布劳尔
J·G·C·拉斯穆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINSTER RES Ltd
Original Assignee
MINSTER RES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MINSTER RES Ltd filed Critical MINSTER RES Ltd
Publication of CN101472586A publication Critical patent/CN101472586A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800232331A 2006-04-21 2007-04-23 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法 Pending CN101472586A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0607952.9 2006-04-21
GBGB0607952.9A GB0607952D0 (en) 2006-04-21 2006-04-21 Novel treatment

Publications (1)

Publication Number Publication Date
CN101472586A true CN101472586A (zh) 2009-07-01

Family

ID=36581049

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800232331A Pending CN101472586A (zh) 2006-04-21 2007-04-23 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法

Country Status (7)

Country Link
US (1) US20090318414A1 (https=)
EP (1) EP2012783A1 (https=)
JP (1) JP2009534367A (https=)
CN (1) CN101472586A (https=)
CA (1) CA2649590A1 (https=)
GB (1) GB0607952D0 (https=)
WO (1) WO2007125287A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
MX373274B (es) 2014-04-23 2020-04-16 Takeda Pharmaceuticals Co Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer.
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
GB0008921D0 (en) * 2000-04-11 2000-05-31 Smithkline Beecham Plc Method of treatment
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
NZ533566A (en) * 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
GB0428180D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy

Also Published As

Publication number Publication date
JP2009534367A (ja) 2009-09-24
GB0607952D0 (en) 2006-05-31
CA2649590A1 (en) 2007-11-08
US20090318414A1 (en) 2009-12-24
WO2007125287A1 (en) 2007-11-08
EP2012783A1 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
KR101615108B1 (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
US20150352107A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
CZ284363B6 (cs) Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
KR20150023902A (ko) 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
CN101472586A (zh) 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法
BG63190B1 (bg) Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система
JP2019502686A (ja) 消化管括約筋機能障害の治療へのｓＧＣ刺激薬の使用
EP1838310A1 (en) Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
KR102892626B1 (ko) 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도
US20040023951A1 (en) Combination therapy for treatment of psychoses
JP6420923B1 (ja) 医薬
WO2019023175A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
CN120983432A (zh) 烟碱和第二代抗精神病药联合在制备缓解双相抑郁药物中的应用
TW201919704A (zh) 利用吡啶斯的明（pyridostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090701